hVIVO (LON:HVO) Trading Up 14.4% - Here's What Happened

hVIVO plc (LON:HVO - Get Free Report) shares rose 14.4% on Monday . The company traded as high as GBX 10 ($0.14) and last traded at GBX 9.95 ($0.13). Approximately 31,066,111 shares were traded during mid-day trading, an increase of 742% from the average daily volume of 3,690,392 shares. The stock had previously closed at GBX 8.70 ($0.12).

Analysts Set New Price Targets

Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research note on Friday, May 30th.

hVIVO Trading Up 2.5%

The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The company has a 50 day simple moving average of GBX 15.92 and a two-hundred day simple moving average of GBX 17.70. The company has a market cap of £75.43 million, a PE ratio of 4.40 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last released its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Sell-side analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.